Drug Profile
Research programme: haemophilia and lysosomal therapeutics - REGiMMUNE
Alternative Names: RGI 5000Latest Information Update: 24 Aug 2023
Price :
$50
*
At a glance
- Originator REGiMMUNE
- Class Enzymes; Small molecules
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Haemophilia; Lysosomal storage diseases
Highest Development Phases
- Discontinued Haemophilia; Lysosomal storage diseases
Most Recent Events
- 24 Aug 2023 Discontinued - Preclinical for Haemophilia in Japan (unspecified route)
- 24 Aug 2023 Discontinued - Preclinical for Lysosomal storage diseases in Japan (unspecified route)
- 28 Oct 2019 No recent reports of development identified for preclinical development in Haemophilia in Japan